SMO and neoplasm: The idea that differential binding of ligands to the various Smo domains might regulate the outcome of Smo signaling was previously suggested by the observation that binding of different inhibitors to Smo TMD causes structural changes that inhibit cholesterol binding and tumor growth (Byrne et al., 2016; Luchetti et al., 2016; Xiao et al., 2017).